MedTrace Logo

Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.

NCT02063126 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-02-19

No results posted yet for this study

Summary

The main objective is evaluate to safety and efficacy of oral Reconnect ® (food supplementation composed by Coenzyme Q10, NADH, phosphoserine y vitamin C) on the maximum HR during an exercise test in CFS

Conditions

  • Chronic Fatigue Syndrome

Interventions

DIETARY_SUPPLEMENT

ReConnect (NADH plus CoQ10)

ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch) Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)

DIETARY_SUPPLEMENT

placebo

placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)

Sponsors & Collaborators

  • VITAE NATURAL NUTRITION, S.L.

    collaborator UNKNOWN

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Jose Alegre-Martin, MD, PhD · Vall d'Hebron University Hospital Research Institute. Internal Medicine Unit.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-01-31
Completion
2013-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02063126 on ClinicalTrials.gov